BioGaia AB (CHIX:BIOGBS) Interest Coverage: 2,130.45 (As of Jun. 2026) — 498% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BIOGBS BioGaia AB CHIX:BIOGBS
100 GF Score
Price kr120.20
GF Value kr135.90
! 1 Warning Sign
View Full Analysis

What is BioGaia AB Interest Coverage?

BioGaia AB CHIX:BIOGBS 100 Interest Coverage is 2,130.45 as of Jun. 2026, which is 498% above its 10-year median of 356.45. GuruFocus rates CHIX:BIOGBS with a GF Score™ of 100/100 and a GF Value™ of kr135.90. The stock has 1 warning sign investors should review. Among 684 Drug Manufacturers companies, BioGaia AB ranks better than 75.29% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. BioGaia AB's Operating Income for the three months ended in Jun. 2026 was kr132 Mil. BioGaia AB's Interest Expense for the three months ended in Jun. 2026 was kr-0 Mil. BioGaia AB's interest coverage for the quarter that ended in Jun. 2026 was 2,130.45. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

BioGaia AB has no debt.

The historical rank and industry rank for BioGaia AB's Interest Coverage or its related term are showing as below:

CHIX:BIOGBs' s Interest Coverage Range Over the Past 10 Years
Min: 62.11   Med: 356.45   Max: 1598.45
Current: 74.96


CHIX:BIOGBs's Interest Coverage is ranked better than
75.29% of 684 companies
in the Drug Manufacturers industry
Industry Median: 12.765 vs CHIX:BIOGBs: 74.96

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


BioGaia AB  (CHIX:BIOGBs) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


BioGaia AB Interest Coverage Related Terms


BioGaia AB Interest Coverage Historical Data

* Premium members only.

The historical data trend for BioGaia AB's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

BioGaia AB Interest Coverage Chart

BioGaia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 214.22 62.11 545.00 283.49 74.62

BioGaia AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.93 23.97 526.10 50.73 2,130.45

CHIX:BIOGBS vs ZTS: Interest Coverage Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB Interest Coverage vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Interest Coverage distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Interest Coverage falls into.


CHIX:BIOGBS
100GF Score
BioGaia AB CHIX:BIOGBS
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioGaia AB Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioGaia AB's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, BioGaia AB's Interest Expense was kr-6 Mil. Its Operating Income was kr452 Mil. And its Long-Term Debt & Capital Lease Obligation was kr0 Mil.

Interest Coverage=-1* Operating Income (A: Dec. 2025 )/Interest Expense (A: Dec. 2025 )
=-1*451.971/-6.057
=74.62

BioGaia AB's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Here, for the three months ended in Jun. 2026, BioGaia AB's Interest Expense was kr-0 Mil. Its Operating Income was kr132 Mil. And its Long-Term Debt & Capital Lease Obligation was kr0 Mil.

Interest Coverage=-1* Operating Income (Q: Jun. 2026 )/Interest Expense (Q: Jun. 2026 )
=-1*132.088/-0.062
=2,130.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 2,130.45 mean?
BioGaia AB (CHIX:BIOGBS) has a Interest Coverage of 2,130.45 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BioGaia AB and its competitors. This is 498% above median its historical median of 356.45. Over the past decade, BioGaia AB's Interest Coverage has ranged from 62.11 to 1,598.45. According to the industry distribution chart, BioGaia AB ranks #169 out of 684 companies in the Drug Manufacturers industry, placing it in the top 24.7%.
Is BioGaia AB's Interest Coverage too high?
BioGaia AB's current Interest Coverage of 2,130.45 is 498% above median its 10-year median of 356.45. Over the past 10 years, this metric has ranged from a low of 62.11 to a high of 1,598.45. The Drug Manufacturers industry median Interest Coverage is 12.77. BioGaia AB's value of 2,130.45 is 16589.8% above this industry median. Based on the distribution chart, BioGaia AB ranks #169 out of 684 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #169 out of 684 companies for Interest Coverage. This places BioGaia AB in the top 25% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.77. BioGaia AB's value of 2,130.45 is 16589.8% above this benchmark. Historically, BioGaia AB's own Interest Coverage has ranged from 62.11 to 1,598.45 over the past decade. While the company's 10-year median is 356.45 vs. the industry median of 12.77, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Interest Coverage of 2,130.45 is 16589.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Interest Coverage is 2,130.45, which is 498% above median its own 10-year median of 356.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (CHIX:BIOGBS) has a current Interest Coverage of 2,130.45. The stock's GF Value™ is kr135.90, compared to a current price of kr120.20 — trading 11.6% below its estimated fair value. The current Interest Coverage is 2,130.45, which is 498% above median its 10-year median of 356.45 and 16589.8% above the Drug Manufacturers industry median of 12.77. BioGaia AB's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For BioGaia AB (CHIX:BIOGBS), the current Interest Coverage is 2,130.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGaia AB (CHIX:BIOGBS) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of kr120.20 is trading 11.6% below its estimated GF Value™ of kr135.90.

Key valuation signals for CHIX:BIOGBS:

  • Interest Coverage: 2,130.45 (498% above median its 10-year median of 356.45)
  • GF Value™: kr135.90 vs. price of kr120.20 (11.6% below fair value)
  • GF Score™: 100/100 with 1 warning sign
  • Industry Position: 16589.8% above the Drug Manufacturers median (#169 of 684)

No single metric tells the full story. See the CHIX:BIOGBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score

Get the complete analysis for CHIX:BIOGBS

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr120.20
Price
kr135.90
GF Value